• Qualigen Therapeutics Inc (NASDAQ: QLGN) has agreed to acquire a majority stake in NanoSynex Ltd, an Israeli-based developer of next-generation diagnostics technology.

• NanoSynex's Antimicrobial Susceptibility Testing (AST) platform provides rapid, accurate, and personalized tests for bacterial infections to quickly match the correct antibiotics to treat a patient's particular infection.

• Antibiotic misuse and overuse have given rise to antibiotic-resistant bacteria, commonly known as superbugs. The World Health Organization has called it one of the top ten global public health threats facing humanity.

• NanoSynex's AST platform aims to enable better targeting of antibiotics for faster and more efficacious treatment, reducing hospital mortality and morbidity rates.

• The purchase consideration primarily includes a stock-for-stock acquisition and an initial $600,000 cash investment in NanoSynex.

• Price Action: QLGN shares are up 2.83% at $0.57 during the market session on the last check Tuesday.

See more from Benzinga

• Why Kymera Therapeutics Shares Are Falling Today

• Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

Don't miss real-time alerts on your stocks - joinBenzinga Profor free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.